Definium Therapeutics
DFTX
181 hedge funds and large institutions have $271M invested in Definium Therapeutics in 2025 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 57 increasing their positions, 49 reducing their positions, and 27 closing their positions.
58% more call options, than puts
Call options by funds: $6.9M | Put options by funds: $4.38M
16% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 49
13% more capital invested
Capital invested by funds: $241M → $271M (+$30.5M)
0.71% more ownership
Funds ownership: 54.61% → 55.32% (+0.71%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less funds holding
Funds holding: 190 → 181 (-9)
33% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 27
Top Buyers
| 1 |
Marshall Wace
London,
United Kingdom
|
+$5.45M |
| 2 |
CC
Commodore Capital
New York
|
+$3.12M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.67M |
| 4 |
ABG
Ally Bridge Group
New York
|
+$2.21M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.32M |
Top Sellers
DFTX Hedge Fund Activity: Q2 2025 in Review
181 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q2 2025, worth a combined $271M — up 13% from $241M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of DFTX and 18 opened new positions — a net loss of 9 holders — while 49 trimmed existing stakes and 57 added.
The largest buyer was Marshall Wace, adding an estimated $5.45M. The largest seller was Octagon Capital Advisors, cutting an estimated $5.84M.
- 181 institutional investors held Definium Therapeutics (DFTX) as of Q2 2025, down from 190 in Q1 2025.
- Funds reported $271M of Definium Therapeutics stock for Q2 2025, up 13% quarter-over-quarter.
- 18 funds opened new Definium Therapeutics positions in Q2 2025 and 27 closed out, a net change of -9 holders.
- The largest Definium Therapeutics buyer in Q2 2025 was Marshall Wace, an estimated $5.45M added.
- The largest Definium Therapeutics seller in Q2 2025 was Octagon Capital Advisors, an estimated $5.84M sold.
Based on aggregated 13F filings for Q2 2025.